close

Login

Library
Shopping Cart
Drug DB
Remember Me
Forgot password/Login issues?
loading animation for AJAX calls
 
 
Direct (781) 489-7301,  Toll Free (866) 285-7215

Search

Search

Choose your License

loading animation for AJAX calls

2010 Pharmaceuticals Research Review

REPORT HIGHLIGHTS

  • The global ophthalmic market grew to $15.5 billion in 2009, showing resistance to the global recession.  The sector will continue to grow through 2014 to $20.6 billion, a compound annual growth rate (CAGR) of 5.9%.
  • Total sales of drug-device combination products worldwide were valued at $12 billion in 2008. The overall market is increasing at a compound annual growth rate (CAGR) of 14.5% per year and thus sales are projected to reach $27 billion by 2014. Overall, sales in the U.S. represent about a third of total industry revenues.
  • The global cardiovascular market was valued at $140.7 billion in 2009, and is expected to continue to grow in 2010 to $144.5 billion by a compound annual growth rate (CAGR) of 2.7%.  The sector will experience a sizable reduction in the early portion of the forecast period, and then slowly rise to a net small reduction by 2015 on a CAGR basis of -0.7%, to a figure of $139.8 billion.

REPORT SCOPE

FOREWORD 

The economic slowdown has accentuated the fault lines already dividing the pharmaceutical world. Lack of innovation from the large pharma companies, coupled with the patent expiration precipice, has fueled merger and acquisition activity. The in-licensing deals that mirror this trend have been a positive boon for biotech companies with either promising compounds in their pipeline, or promising platforms – most especially for delivering RANi drugs, or uncovering pathways previously held within the domain of academia only.
 
As a shadow looming behind this field there have also been dramatic change to U.S. health policy through legislation, and the awakening of the increasingly alluring emerging markets in China and India – still small in comparison - but future engines for high growth.
 
BCC Research has provided comprehensive coverage of pharmaceutical markets for many years, and we are now increasing our production of these research reports. This review of pharmaceutical market research conducted in 2010 is meant to provide a sampling of the type of quantitative market information, analysis and guidance that has been aiding business decision-making since BCC was founded in 1971.
 
This review includes highlights from the following reports on pharmaceutical markets published BCC Research: 
  • Ophthalmic Therapeutic Drugs: Technologies and Global Markets
  • Global Markets for Orphan Drugs
  • Drug-Device Combinations: The Global Market
  • Cardiovascular Therapeutic Drugs: Technologies and Global Markets
  • Alzheimer's Disease Therapeutics and Diagnostics: Global Markets
  • Antipsychotic Drugs: Technologies and Global Markets
  • Ubiquitin Proteosome Drugs: Cancer and Neurodegenerative Disorder Markets
  • Oncology Adjuvants: Technologies and Global Markets
We hope you find this Research Review valuable, and we look forward to serving our customers’ pharmaceutical market research needs
 
Chris Spivey
Senior Editor
BCC Research

REPORT TOC

  Title/Chapter Name Pages Price
2010 Pharmaceuticals Research Review 201 $855
Chapter- 1: FOREWORD - Complimentary 1 $0
  Show Details
Chapter- 2: OPHTHALMIC THERAPEUTIC DRUGS: TECHNOLOGIES AND GLOBAL MARKETS (PHM031C): 17 $150
  Show Details
Chapter- 3: GLOBAL MARKETS FOR ORPHAN DRUGS (PHM038C) 25 $160
  Show Details
Chapter- 4: DRUG-DEVICE COMBINATIONS: THE GLOBAL MARKET (PHM045B) 32 $204
  Show Details
Chapter- 5: CARDIOVASCULAR THERAPEUTIC DRUGS: TECHNOLOGIES AND GLOBAL MARKETS (PHM024B) 23 $147
  Show Details
Chapter- 6: ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS: GLOBAL MARKETS (PHM062A) 18 $115
  Show Details
Chapter- 7: ANTIPSYCHOTIC DRUGS: TECHNOLOGIES AND GLOBAL MARKETS (PHM063A) 27 $172
  Show Details
Chapter- 8: UBIQUITIN PROTEOSOME DRUGS: CANCER AND NEURODEGENERATIVE DISORDER MARKETS (PHM066A) 29 $185
  Show Details
Chapter- 9: ONCOLOGY ADJUVANTS: TECHNOLOGIES AND GLOBAL MARKETS (PHM067A) 29 $185
  Show Details
 
  List of Tables
  List of Figures
 
Latest Version
PHM099C - December 2012